ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

Our Pipeline

Our portfolio is led by eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor that has the potential to improve upon current biologics used to treat allergic disease. We are also developing farudodstat, a potent oral inhibitor of the enzyme DHODH, as a potential first-in-class treatment for alopecia areata.

Program Target Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated milestones
Eblasakimab IL-13Rα1 Atopic dermatitis
Biologic naïve
 Phase 3 initiation in 2024
Phase 2b biomarker data 2H 2023
Dupilumab experienced
Type 2-driven disease
Farudodstat DHODH Alopecia areata
Phase 2a interim topline data 1Q 2024


Eblasakimab

Phase 2

Potential first-in-class antibody targeting the IL 13 receptor in moderate-to-severe atopic dermatitis

Read more about Eblasakimab

Farudodstat

Phase 2

Potent, oral DHODH inhibitor with the potential to be a first-in-class treatment for alopecia areata

Read more about Farudodstat

Therapeutic Areas

We focus on atopic dermatitis, alopecia areata and Type 2-driven diseases.

Atopic dermatitis

Atopic dermatitis

Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide. Up to one-third of adult atopic dermatitis patients are considered moderate-to-severe, for which currently available therapeutics are limited and management is challenging in the majority of cases.

ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a first-in-class therapy for atopic dermatitis. ASLAN004 is currently undergoing a phase 1 study for the treatment of atopic dermatitis. The SAD portion of the study was completed in the second quarter of 2019. The MAD portion of the study is ongoing. Positive interim data was announced in March 2021, and top line data is expected in mid-2021.